The
article.
. . 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Table of Contents
Addendum
References
(Page 1, Page
2)
1. Bradley LA, McKendree-Smith NL, Alarcon GS. Pain complaints in
patients with fibromyalgia versus chronic fatigue syndrome. Curr
Rev Pain. 2000;4:148-157.
2. Pongratz DE. Sievers M. Fibromyalgia-symptom
or diagnosis: a definition of the position. Scand J Rheumatol (Suppl).
2000;113:3-7.
3. Harding SM. Sleep in fibromyalgia patients: subjective
and objective findings. Am J Med Sci. 1998;315:367-76.
4.
Korszun A. Sleep and circadian rhythm disorders in fibromyalgia.
Curr Rheumatol Rep. 2000;2:124-30.
5.
Buskila D, Neumann L, Alhoashle A, et al. Fibromyalgia syndrome in
men. Semin Arthritis Rheum. 2000;30:47-51.
6.
Anderberg UM, Marteinsdottir I, Theorell T, et al. The impact of life
events in female patients with fibromyalgia and in female healthy
controls. Eur Psychiatry. 2000;15:295-301.
7.
Jeschonneck M, Grohmann G, Hein G, et al. Abnormal microcirculation
and temperature in skin above tender points in patients with fibromyalgia.
Rheumatology (Oxford). 2000;39:917-21.
8.
Shanklin DR, Stevens MV, Hall MF, et al. Environmental immunogens and
T-cell-mediated responses in fibromyalgia: evidence for immune
dysregulation and determinants of granuloma formation. Exp
Mol Pathol.
2000;69:102-18.
9. Pongratz DE, Spath M. Morphologic aspects of fibromyalgia. Z
Rheumatol. 1998;57 Suppl 2:47-51.
10. Kwiatek R, Barnden
L, Tedman R, et al. Regional cerebral blood flow in fibromyalgia:
single-photon-emission computed tomography evidence
of reduction in the pontine tegmentum and thalami. Arthritis
Rheum. 2000;43:2823-33.
11. Bradley LA, McKendree-Smith
NL, Alberts KR, et al. Use of neuroimaging to understand abnormal pain
sensitivity in fibromyalgia. Curr
Rheumatol Rep. 2000;2:141-148.
12. Neeck G. Neuroendocrine and
hormonal perturbations and relations to the serotonergic system in
fibromyalgia patients. Scand
J Rheumatol (Suppl). 2000;113:8-12.
13. Ackenheil M.
Genetics and pathophysiology of affective disorders: relationship to
fibromyalgia. Z Rheumatol. 1998;57
Suppl 2:5-7.
14. Bondy B, Spaeth M, Offenbaecher M, et al. The T102C
polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol
Dis. 1999;6:433-9.
15. Wikner J, Hirsch U, Wetterberg L, et al.
Fibromyalgia- a syndrome associated with decreased nocturnal melatonin
secretion. Clin
Endocrinol (Oxford). 1998;49:179-83.
16. Klein R, Berg PA. High
incidence of antibodies to 5-hydroxytryptamine, gangliosides and phospholipids
in patients with chronic fatigue and
fibromyalgia syndrome and their relatives: evidence for a clinical
entity of both disorders. Eur J Med Res. 1995;1:21-6.
17.
Coplan JD, Tamir H, Calaprice D, et al. Plasma anti-serotonin and serotonin
anti-idiotypic antibodies are elevated in panic disorder.
Neuropsychopharmacology. 1999;20:386-91.
18.
Klein R, Bansch M, Berg PA. Clinical relevance of antibodies against
serotonin and gangliosides in patients with primary fibromyalgia syndrome.
Psychoneuroendocrinology. 1992;17:593-8.
19.
Wolfe F, Russell IJ, Vipraio G, et al. Serotonin levels, pain threshold,
and fibromyalgia symptoms in the general population. J
Rheumatol.
1997;24:555-9.
20. Ernberg M, Hedenberg-Magnusson B, Alstergren P, et
al. The level of serotonin in the superficial masseter muscle in relation
to local
pain and allogynia. Life Sci. 1999;65:313-25.
21.
Khawaja AM, Rogers DF. Tachykinins: receptor to effector. Int
J Biochem Cell Biol. 1996;28:721-38.
22. Murphey R. Primary amino
acid sequence of guinea-pig substance P. Neuropeptides. 1989;14:105-10.
23.
Lee S, Suh YH, Kim S, et al. Comparison of the structures of beta amyloid
peptide (25-35) and substance P in trifluoroethanol/water solution.
J Biomol Struct Dyn. 1999;17:381-91.
24.
Patel AB, Srivastava S, Coutinho E, et al. Replacement of phe(8) in
substance P by tyr (Tyr(8)-SP) alters the conformation of the peptide
in DMSO, water, and lipid bilayers. Biopolymers. 1999;50:602-12.
25.
Cowsik SM, Lucke C, Ruterjans H. Lipid-induced conformation of substance
P. J Biomol Struct Dyn. 1997;15:27-36.
26.
Ploux O, Lavielle S, Chassaing G, et al. Interaction of tachykinins
with their receptors studied with cyclic analogues of substance P and
neurokinin B. Proc Natl Acad Sci U
S A. 1987;84:8095-9.
27. Takeuchi Y, Shands EF, Beusen DD, et al. Derivation
of a three-dimensional pharmacophore model of substance P antagonists
bound to the neurokinin-1
receptor. J Med Chem. 1998;41:3609-23.
28.
Grdadolnik SG, Mierke DF, Byk G, et al. Comparison of the conformation
of active and nonactive backbone cyclic analogs of substance P as a
tool to elucidate features of the bioactive conformation: NMR and molecular
dynamics in DMSO and water. J Med Chem. 1994;37:2145-52.
29.
Meiworm L, Jakob E, Walker UA, et al. Patients with fibromyalgia benefit
from aerobic endurance exercise. Clin
Rheumatol. 2000;19:253-7.
30. Sprott H, Franke S, Kluge H, et
al. Pain treatment of fibromyalgia by acupuncture. Rheumatol Int. 1998;18:35-6.
31.
Maes M, Verkerk R, Delmeire L, et al. Serotonergic markers and lowered
plasma branched-chain-amino acid concentrations in fibromyalgia.
Psychiatry Res. 2000;97:11-20.
32. Citera
G, Arias MA, Maldonado-Cocco JA, et al. The effect of melatonin in
patients with fibromyalgia: a pilot study. Clin
Rheumatol. 2000;19:9-13.
33. Merchant RE, Carmack CA, Wise CM.
Nutritional supplementation with Chlorella pyrenoidosa for patients
with fibromyalgia syndrome:
a pilot study. Phytother Res. 2000;14:167-73.
34.
Wolf H. Preclinical and clinical pharmacology of the 5-HT3 receptor
antagonists. Scand J Rheumatol (Suppl).
2000;113:37-45.
35. Hrycaj P, Stratz T, Mennet P, et al. Pathogenetic
aspects of responsiveness to ondansetron (5-hydroxytryptamine type
3 receptor antagonist) in
patients with primary fibromyalgia syndrome – a preliminary study. J Rheumatol. 1996;23:1418-23.
36.
O'Malley PG, Balden E, Tomkins G, et al. Treatment of fibromyalgia
with antidepressants. A meta-analysis. J Gen
Intern Med. 2000;15:659-66.
37. Goldenberg D, Mayskiy M, Mossey
C, et al. A randomized, double-blind crossover trial of fluoxetine
and amitriptyline in the treatment of
fibromyalgia. Arthritis Rheum. 1996;39:1852-9.
38.
Lautenschlager J. Present state of medication therapy in fibromyalgia
syndrome. Scand J Rheumatol (Suppl).
2000;113:32-6.
39. Ninan PT. Use of venlafaxine in other psychiatric
disorders. Depress
Anxiety. 2000;12 Suppl 1:90-4.
40. Birdsall TC. 5-Hydroxytryptophan:
a clinically-effective serotonin precursor. Altern Med Rev. 1998;3:271-80.
41.
Haus U, Varga B, Stratz T, et al. Oral treatment of fibromyalgia with
tropisetron given over 28 days: influence on functional and vegetative
symptoms, psychometric parameters and pain. Scand
J Rheumatol (Suppl).
2000;113:55-8.
42. Farber L, Stratz T, Bruckle W, et al. Efficacy and
tolerability of tropisetron in primary fibromyalgia – a highly
selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia
Study Group. Scand J Rheumatol (Suppl).
2000;113:49-54.
43. Muller W, Stratz T. Results of the intravenous administration
of tropisetron in fibromyalgia patients. Scand
J Rheumatol (Suppl).
2000;113:59-62.
44. De Simone C. Misefari A, Covelli V, et al. Effects
of substance P on the spontaneous binding of Salmonella minnesota R345
(Rb) to human
peripheral blood lymphocytes. J Clin Lab Anal. 1989;3:345-9.
45.
Annunziata P, Cioni C, Toneatto S, et al. HIV-1 gp120 increases the
permeability of rat brain endothelium cultures by a mechanism involving
substance P. AIDS. 1998;12:2377-85.
46.
Nasralla M, Haier J, Nicolson GL. Multiple mycoplasmal infections detected
in blood of patients with chronic fatigue syndrome and/or
fibromyalgia syndrome. Eur J Clin Microbiol
Infect Dis. 1999;18:859-65.
47. Dionisio D, Valassina M, Mata
S, et al. Encephalitis caused directly by Mycoplasma pneumoniae. Scand J Infect Dis. 1999;31:506-9.
48.
Komatsu H, Kuroki S, Shimizu Y, et al. Mycoplasma pneumoniae meningoencephalitis
and cerebellitis with antiganglioside antibodies. Pediatr
Neurol. 1998;18:160-4.
49. Caceres ME, de los Reyes EC, Khan
R, et al. Acute encephalopathy and intractable seizures in a 10-year-old
boy. Semin Pediatr Neurol.
1999;6:229-31.
50. Launes J, Paetau A, Linnavuori K, et al. Direct invasion
of the brain parenchyma by Mycoplasma pneumoniae. Acta
Neurol Scand. 1997;95:374.
51. Yirmiya R, Weidenfeld J, Barak
O, et al. The role of brain cytokines in mediating the behavioral and
neuroendocrine effects of intracerebral
Mycoplasma fermentans. Brain Res. 1999;829:28-38.
52.
Buskila D, Shnaider A, Neumann L, et al. Fibromyalgia in hepatitis
C virus infection. Another infectious disease relationship. Arch
Intern Med. 1997;157:2497-500.
53. Rivera J, de Diego A, Trinchet
M, et al. Fibromyalgia-associated hepatitis C virus infection. Br J Rheumatol. 1997;36:981-5.
54.
Machtey I. Chlamydia pneumoniae antibodies in myalgia of unknown cause
(including fibromyalgia). Br J Rheumatol. 1997;36:1134.
55.
Meyer RD, Kaplan MH, Ong M, et al. Cutaneous lesions in disseminated
mucormycosis. JAMA. 1973;225:737-8.
56.
Taylor-Robinson D, Furr PM, Davies HA, et al. Mycoplasmal adherence
with particular reference to the pathogenicity of Mycoplasma pulmonis.
Isr J Med Sci. 1981;17:599-603.
57.
Kahane I, Pnini S, Banai M, et al. Attachment of mycoplasmas to erythrocytes:
a model to study mycoplasma attachment to the epithelium
of the host respiratory tract. Isr J Med Sci. 1981;17:589-92.
58.
Shinriki N, Ishizaki K, Ikehata A, et al. Mode of degradation of tRNAs
with ozone. Nucleic Acids Symp Ser. 1981;24:211-4.
59.
Bradford RW, Allen HW, Hildreth DJ. The significance of fungemia in
modern clinical experience. BRI Monograph #56. 1999, Bradford Research
Institute, 1180 Walnut Ave., Chula Vista, California 91911.
60. Bradford
RW, Allen HW. The Biochemical
Basis of Live Cell Therapy.
Chula Vista, California: The Robert W. Bradford Foundation, 1986.
61.
Bradford RW, Allen HW. Inter-Reaction of Neuro-Endocrine Systems
in Stress, Pathology and Peripheral Blood Morphology. Bradford Research
Institute Monograph #59, 55 pgs.
62. Waylonis GW, Heck W. Fibromyalgia
syndrome: New associations.
Am J Phys Med Rehabil. 1992;71:343-8.
63.
Kosek E, Ekholm J, Hansson P. Sensory dysfunction in fibromyalgia patients
with implications for pathogenic mechanisms. Pain. 1996;68:375-83.
64.
Dinerman H, Goldenberg DL, Felson DT. A prospective evaluation of 118
patients with the fibromyalgia syndrome: prevalence of Raynaud's
phenomenon, sicca symptoms, ANA, low complement, and Ig deposition
at the dermal-epidermal junction. J Rheumatol. 1986;13:368-73.
65.
Bell IR, Baldwin CM, Schwartz GE. Illness from low levels of environmental
chemicals: relevance to chronic fatigue syndrome and fibromyalgia.
Am J Med. 1998;105(3A):74S-82S.
66.
Maes M, Libbrecht I, Van Hunsel F, et al. The immune-inflammatory pathophysiology
of fibromyalgia: increased serum soluble gp130, the
common signal transducer protein of various neurotropic cytokines.
Psychoneuroendocrinology. 1999;24:371-83.
67.
Deodhar AA, Figher RA, Blacker CV, et al. Fluid retention syndrome
and fibromyalgia. Br J Rheumatol. 1994;33:576-82.
68.
Pesle G, Triboulet F, Gharbi N, et al. About 35 cases of pleural aspergillosis. Ooumon Coeur. 1980;36:7-11.
69.
Roux JP, Koussa A, Cajot MA, et al. Primary Aspergillus endocarditis.
Apropos of a case and review of the international literature. Ann
Chir. 1992;46:110-5.
70. Eberle DE, Evans RB, Johnson
RH. Disseminated North American blastomycosis. Occurrence with clinical
manifestations of adrenal insufficiency. JAMA. 1977;238:2629-30.
71.
Helm TN, Longworth DL, Hall GS, et al. Case report and review of resolved
fusariosis. J Am Acad Dermatol. 1990;23:393-8.
72.
Harrison TS, Nong S, Levitz SM. Induction of human immunodificiency
virus type 1 expression in monocytic cells by Cryptococcus neoformans
and Candida albicans. J Infect Dis. 1997;176:485-91.
73.
Huffnagle GB, Chen GH, Curtis JL, et al. Down-regulation of the afferent
phase of T cell-mediated pulmonary inflammation and immunity
by a high melanin-producing strain of Cryptococcus neoformans. J
Immunol. 1995;155:3507-16.
74. Matthews R, Burnie J.
The role of hsp90 in fungal infections.
Immunol Today. 1992;13:345-8.
75. Tournas
VH, Stack ME. Production of alternariol and alternariol methyl ether
by Alternaria alternata grown on fruits at various temperatures.
J Food Prot. 2001;64:528-32.
76. Li
FQ, Toyazaki N, Yoshizawa T. Production of alternaria mycotoxins by
Alternaria alternata isolated from weather-damaged wheat. J
Food Prot. 2001;64:567-71.
77. Personal communication. Norbert
Becquet, MD, Little Rock, AK, Prof. Robert W. Bradford, et al. Ingles
Integrative Medical Hospital,
Mexico, Albert MacKenzie, MD, Los Angeles, CA, Prof. Ann Marie Dixon,
NMD, et al. Washington, DC.
78. Nicolson, GL, et al. Med Sentinel. 1999;4:172-6.
79.
Buchanan KL, Murphy JW, What makes Cryptococcus neoformans a pathogen?
Emerg Infect Dis. 1998;4:71-83.
80.
Wang Y, Aisen P, Casadevall A. Melanin, melanin "ghosts",
and melanin composition in Cryptococcus neoformans. Infect
Immun. 1996;64:2420-4.
Continued on Page
2
|